StockNews.com Initiates Coverage on Catalent (NYSE:CTLT)

Analysts at StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the stock.

Catalent Price Performance

Shares of NYSE CTLT opened at $63.48 on Tuesday. Catalent has a twelve month low of $41.15 and a twelve month high of $63.50. The firm has a fifty day simple moving average of $62.87 and a 200 day simple moving average of $60.74. The company has a market capitalization of $11.52 billion, a PE ratio of -28.09, a P/E/G ratio of 2.69 and a beta of 1.15. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period last year, the firm posted ($0.10) earnings per share. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. On average, sell-side analysts forecast that Catalent will post 0.78 EPS for the current year.

Insider Transactions at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.31% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTLT. Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in Catalent by 1.1% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock valued at $1,179,000 after acquiring an additional 220 shares during the last quarter. Crossmark Global Holdings Inc. increased its holdings in Catalent by 2.6% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock worth $553,000 after acquiring an additional 229 shares during the period. GAMMA Investing LLC increased its holdings in Catalent by 26.9% during the 3rd quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock worth $79,000 after acquiring an additional 278 shares during the period. Blue Trust Inc. increased its holdings in Catalent by 88.7% during the 4th quarter. Blue Trust Inc. now owns 615 shares of the company’s stock worth $37,000 after acquiring an additional 289 shares during the period. Finally, Greenleaf Trust increased its holdings in Catalent by 10.7% during the 3rd quarter. Greenleaf Trust now owns 4,294 shares of the company’s stock worth $260,000 after acquiring an additional 416 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.